2016/3 GaBI Journal Table of Contents

Published in: Volume 5 / Year 2016 / Issue 3
Category: 2016/3 GaBI Journal Table of Contents
Visits: 1679 total, 2 today


Editor’s Letter

Latest features in GaBI Journal, 2016, Issue 3

Letters to the Editor

Is the EU ready for non-biological complex drug products?


Biosimilars: achieving long-term savings and competitive markets

Review Article

Current state of subsequent entry biologics (biosimilars) in Canada: a view from regulatory, reimbursement, clinician, and patient perspectives

The generic medicines system in Italy: scenarios for sustainable growth


Pharmacovigilance on biologicals and biosimilars: a Danish perspective

Regional management of biosimilars in Germany

Are the perspectives regarding the use of biosimilars in the setting of haematology and blood and marrow transplant changing?

Biosimilars in Italy: a gastroenterologist’s view

Meeting Report

First Turkish interactive workshop on regulation and approval of similar biotherapeutic products/biosimilars, 2–3 March 2016, Ankara, Turkey

Demonstrating interchangeability and biosimilarity for US biosimilars

Special Report

US FDA proposals for naming of biologicals and labelling of biosimilars

Competitive effects on the generics industry

Go Back Print

Leave a Reply